CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OLIGOMED focuses on developing synthetic oligonucleotide therapies for genetic diseases by integrating academic and industry expertise. The project aims to create innovative treatment options through advanced research and training for early-stage researchers.
The use of synthetic oligonucleotides (ONs, short DNA or RNA strands) in the treatment of genetic diseases is a rapidly growing field, and the most promising alternative to gene therapy or small molecules.
Most pharmaceutical companies shift from in-house platform development to product-specific licensing and co-development to get ON based therapies past clinical trials.
Therefore there is a growing and currently unmet need for a combined academic and industry-based multidisciplinary research to…
UNIVERSITY OF SOUTHAMPTON
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Stockholm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Poland, WARSZAWA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Sweden, Stockholm
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
